Effects of GBR 12909 and cocaine on cocaine-maintained behavior in rhesus monkeys

https://doi.org/10.1016/0376-8716(93)90031-KGet rights and content

Abstract

The reinforcing effect of the high affinity dopamine reuptake inhibitor GBR 12909 (1-[2-[bis(4-fluorophenyl)methoxy]ethyl)-4(3-phenylpropyl)piperazine) was compared with that of cocaine, and the effects of both GBR 12909 and cocaine pretreatments were evaluated on behaviour maintained by cocaine in rhesus monkeys. Increasing dose per injection of intravenously-delivered GBR 12909 or cocaine led to increased rates of lever-press responding. Maximum cocaine-maintained rates were higher and occurred at a smaller dose than maximum rates of GBR 12909-maintained responding. Presession intravenous administration of either GBR 12909 or cocaine (0.32, 1.0 or 3.2 mg/kg) resulted in dose-dependent decreases in rates of cocaine-maintained responding when high doses of cocaine, which engendered high response rates, were available early in the session. Under these conditions, the decrease in response rates was associated primarily with decreases in running rate rather than with a lengthening in post-reinforcement pause times. The decreases in running rate produced by both cocaine and GBR 12909 probably reflect an unconditioned rate-disruptive effect of these drugs on cocaine-reinforced responding rather than a reduction in the reinforcing efficacy of cocaine.

References (21)

There are more references available in the full text version of this article.

Cited by (47)

  • Effects of GPR139 agonism on effort expenditure for food reward in rodent models: Evidence for pro-motivational actions

    2022, Neuropharmacology
    Citation Excerpt :

    Among these, the feeding regimen and therefore degree of satiety at the onset of testing would be expected to be particularly important. It is well known that satiety manipulations markedly influence the vigor of responding in operant tasks for gustatory reward, e.g. pre-test feeding reduces food motivation and breakpoints (Hailwood et al., 2018; Salamone et al., 1991; Skjoldager, 1993). Notably, our rats were maintained under a moderately restrictive feeding regimen, which enhanced motivation for food and the effort expended to receive sucrose reward.

  • Noradrenergic circuits and signaling in substance use disorders

    2022, Neuropharmacology
    Citation Excerpt :

    Lesion of the VNB also had no effect on the maintenance phase of cocaine self-administration (Roberts et al., 1977). Further, selective NET inhibitors are generally not self-administered, while DAT inhibitors are self-administered (Skjoldager et al., 1993; Wee et al., 2006; Woolverton, 1987). Together, these data suggest that NE is not involved in the maintenance of psychostimulant self-administration.

  • Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction

    2008, Biochemical Pharmacology
    Citation Excerpt :

    Such data demonstrate that factors in addition to DAT binding affinity must be involved in mediating the in vivo reinforcing actions of these drugs. GBR12909 has been found to serve as a reinforcer in several species [39–42]. Studies showed that GBR12909 can maintain rates of drug-appropriate responding in animals trained to self-administer cocaine, as well as substitute for cocaine [43–49].

  • Prefrontal cortex D1 modulation of the reinforcing properties of cocaine

    2006, Brain Research
    Citation Excerpt :

    Similarly, hyperlocomotion stimulated by intra-NAcc D1 agonist (SKF 38393) is enhanced 48 h following intra-PFC SCH 23390, although intra-NAcc amphetamine-stimulated hyperlocomotion is diminished 48 h post-infusion (Vezina et al., 1994). Systemic pretreatments with amphetamine (Lynch et al., 1998; Negus and Mello, 2003), GBR 12909 (Skjoldager et al., 1993; Tella, 1995), phentermine (Wojnicki et al., 1999) and a D1 agonist (Platt et al., 2001) all elevate NAcc levels and lead to decreased cocaine self-administration. Previously, we observed elevations in NAcc DA 24 h after intra-PFC infusions of a low dose of the D1 antagonist, SCH23390 (Olsen and Duvauchelle, 2001).

View all citing articles on Scopus
View full text